TABLE 2

Clinical and demographic characteristics, stratified by HIV status, of patients treated with rifampicin-resistant tuberculosis regimens containing delamanid and bedaquiline from November 1, 2015, to August 31, 2017, in Khayelitsha, South Africa

VariableTotal patientsHIV positiveHIV-negativep-value
Patients32 (100.0)18 (100.0)14 (100.0) 
Age at Dlm initiation years35 (30–43)36 (31–43)32 (25–42)0.32
<18 years of age2 (6.3)0 (0.0)2 (14.3)
Male19 (59.4)10 (55.6)9 (64.3)0.62
Body mass index at Dlm initiation kg·m−220.8 (19.5–24.4)#20.5 (19.5–24.9)21.7 (19.6–23.6)#0.86
QTcF at Dlm initiation ms410.5 (387.5–429.0)405.0 (383.0–432.0)415.5 (404.0–426.0)0.63
Diabetic2 (6.3)0 (0.0)2 (14.3)0.18
CD4 count at Dlm initiation cells·mm−391.0 (55.0–215.0)
Antiretroviral therapy at Dlm initiation16 (88.9)
RR-TB disease classification
 Rifampicin mono-resistant TB2 (6.3)2 (11.1)0 (0.0)
 Multidrug-resistant TB3 (9.4)1 (5.6)2 (14.3)
 Pre-XDR-TB injectable1 (3.1)1 (5.6)0 (0.0)
 Pre-XDR-TB fluoroquinolone12 (37.5)5 (27.8)7 (50.0)
 XDR-TB14 (43.7)9 (50.0)5 (35.7)0.46
Previous TB treatment history
 None9 (28.1)3 (16.7)6 (42.9)
 First-line12 (37.5)8 (44.4)4 (28.6)
 Second-line11 (34.4)7 (38.9)4 (28.6)0.26
Disease site
 Pulmonary30 (93.8)17 (94.4)13 (92.9)
 Extrapulmonary2 (4.8)1 (5.6)1 (7.1)1.0
QTcF-prolonging drugs co-administered+
 Clofazimine24 (75.0)13 (72.2)11 (78.6)1.0
 Moxifloxacin0 (0.0)0 (0.0%)0 (0.0)

Data are presented as n (%) or median (interquartile range). Dlm: delamanid; QTcF: QT corrected using the Frederica formula; RR: rifampicin-resistant; TB: tuberculosis; XDR: extensively drug-resistant. #: one missing baseline body mass index; : one missing baseline CD4 count; +: numbers are not mutually exclusive.